Advertisement
Screener

XENETIC BIOSCIENCES, INC. (XBIO) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

XENETIC BIOSCIENCES, INC. Research and Development Expense

XENETIC BIOSCIENCES, INC. (XBIO) reported Research and Development Expense of $552.01 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06

  • XENETIC BIOSCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $552.01K, a 15.92% decline year-over-year.
  • XENETIC BIOSCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $661.44K, a 24.75% decline year-over-year.
  • XENETIC BIOSCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $773.42K, a 25.79% decline year-over-year.
  • XENETIC BIOSCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $756.48K, a 105.57% increase year-over-year.
  • XENETIC BIOSCIENCES, INC. research and development expense for fiscal 2025 was $3.07M, a 6.78% decline from fiscal 2024.
  • XENETIC BIOSCIENCES, INC. research and development expense for fiscal 2024 was $3.29M, a 5.91% decline from fiscal 2023.
  • XENETIC BIOSCIENCES, INC. research and development expense for fiscal 2023 was $3.49M, a 26.75% decline from fiscal 2022.
  • XENETIC BIOSCIENCES, INC. research and development expense for fiscal 2022 was $4.77M, a 50.81% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 12 month
2026-06-30$552.01K
10-Q · filed 2026-08-06
$1.21M
10-Q · filed 2026-08-06
$1.99M
derived: sum of 3 quarters · filed 2026-08-06
$2.74M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$661.44K
10-Q · filed 2026-05-12
$1.43M
derived: sum of 2 quarters · filed 2026-05-12
$2.19M
derived: sum of 3 quarters · filed 2026-05-12
$2.85M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$773.42K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$1.53M
derived: sum of 2 quarters · filed 2026-03-12
$2.19M
derived: sum of 3 quarters · filed 2026-08-06
$3.07M
10-K · filed 2026-03-12
2025-09-30$756.48K
10-Q · filed 2025-11-12
$1.41M
derived: sum of 2 quarters · filed 2026-08-06
$2.29M
10-Q · filed 2025-11-12
$3.33M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$656.56K
10-Q · filed 2026-08-06
$1.54M
10-Q · filed 2026-08-06
$2.58M
derived: sum of 3 quarters · filed 2026-08-06
$2.95M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$879.03K
10-Q · filed 2026-05-12
$1.92M
derived: sum of 2 quarters · filed 2026-05-12
$2.29M
derived: sum of 3 quarters · filed 2026-05-12
$3.22M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$1.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$1.41M
derived: sum of 2 quarters · filed 2026-03-12
$2.34M
derived: sum of 3 quarters · filed 2026-03-12
$3.29M
10-K · filed 2026-03-12
2024-09-30$367.99K
10-Q · filed 2025-11-12
$1.30M
derived: sum of 2 quarters · filed 2025-11-12
$2.25M
10-Q · filed 2025-11-12
$3.22M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$933.77K
10-Q · filed 2025-08-12
$1.88M
10-Q · filed 2025-08-12
$2.85M
derived: sum of 3 quarters · filed 2025-08-12
$3.87M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$944.32K
10-Q · filed 2025-05-13
$1.92M
derived: sum of 2 quarters · filed 2025-05-13
$2.94M
derived: sum of 3 quarters · filed 2025-05-13
$3.84M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$975.63K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18
$2.00M
derived: sum of 2 quarters · filed 2025-03-18
$2.90M
derived: sum of 3 quarters · filed 2025-03-18
$3.49M
10-K · filed 2025-03-18
2023-09-30$1.02M
10-Q · filed 2024-11-12
$1.92M
derived: sum of 2 quarters · filed 2024-11-12
$2.52M
10-Q · filed 2024-11-12
$3.71M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$903.24K
10-Q · filed 2024-08-13
$1.50M
10-Q · filed 2024-08-13
$2.69M
derived: sum of 3 quarters · filed 2024-08-13
$3.09M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$595.28K
10-Q · filed 2024-05-09
$1.79M
derived: sum of 2 quarters · filed 2024-05-09
$2.19M
derived: sum of 3 quarters · filed 2024-05-09
$4.26M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$1.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
$1.59M
derived: sum of 2 quarters · filed 2024-03-21
$3.67M
derived: sum of 3 quarters · filed 2024-03-21
$4.77M
10-K · filed 2024-03-21
2022-09-30$398.80K
10-Q · filed 2023-11-09
$2.48M
derived: sum of 2 quarters · filed 2023-11-09
$3.58M
10-Q · filed 2023-11-09
$4.81M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$2.08M
10-Q · filed 2023-08-10
$3.18M
10-Q · filed 2023-08-10
$4.41M
derived: sum of 3 quarters · filed 2023-08-10
$5.19M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$1.10M
10-Q · filed 2023-05-11
$2.33M
derived: sum of 2 quarters · filed 2023-05-11
$3.11M
derived: sum of 3 quarters · filed 2023-05-11
$3.64M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$1.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22
$2.01M
derived: sum of 2 quarters · filed 2023-03-22
$2.53M
derived: sum of 3 quarters · filed 2023-03-22
$3.16M
10-K · filed 2023-03-22
2021-09-30$780.15K
10-Q · filed 2022-11-09
$1.30M
derived: sum of 2 quarters · filed 2022-11-09
$1.93M
10-Q · filed 2022-11-09
$2.43M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30$524.55K
10-Q · filed 2022-08-11
$1.15M
10-Q · filed 2022-08-11
$1.65M
derived: sum of 3 quarters · filed 2022-08-11
$2.22M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31$629.73K
10-Q · filed 2022-05-12
$1.12M
derived: sum of 2 quarters · filed 2022-05-12
$1.69M
derived: sum of 3 quarters · filed 2022-05-12
$2.00M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$490.79K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22
$1.06M
derived: sum of 2 quarters · filed 2022-03-22
$1.37M
derived: sum of 3 quarters · filed 2022-03-22
$1.73M
10-K · filed 2022-03-22
2020-09-30$573.06K
10-Q · filed 2021-11-12
$880.96K
derived: sum of 2 quarters · filed 2021-11-12
$1.24M
10-Q · filed 2021-11-12
$1.66M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30$307.90K
10-Q · filed 2021-08-12
$667.55K
10-Q · filed 2021-08-12
$1.08M
derived: sum of 3 quarters · filed 2021-08-12
$4.61M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$359.65K
10-Q · filed 2021-05-11
$777.05K
derived: sum of 2 quarters · filed 2021-05-11
$4.30M
derived: sum of 3 quarters · filed 2021-05-11
$4.79M
derived: sum of 4 quarters · filed 2021-05-11
2019-12-31$417.40K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16
$3.94M
derived: sum of 2 quarters · filed 2021-03-16
$4.43M
derived: sum of 3 quarters · filed 2021-03-16
$4.89M
10-K · filed 2021-03-16
2019-09-30$3.52M
10-Q · filed 2020-11-12
$4.01M
derived: sum of 2 quarters · filed 2020-11-12
$4.47M
10-Q · filed 2020-11-12
$4.99M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$487.52K
10-Q · filed 2020-08-12
$951.30K
10-Q · filed 2020-08-12
$1.47M
derived: sum of 3 quarters · filed 2020-08-12
$2.20M
derived: sum of 4 quarters · filed 2020-08-12
2019-03-31$463.78K
10-Q · filed 2020-05-14
$978.51K
derived: sum of 2 quarters · filed 2020-05-14
$1.71M
derived: sum of 3 quarters · filed 2020-05-14
$2.64M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31$514.73K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26
$1.25M
derived: sum of 2 quarters · filed 2020-03-26
$2.18M
derived: sum of 3 quarters · filed 2020-03-26
$2.88M
10-K · filed 2020-03-26
2018-09-30$735.88K
10-Q · filed 2019-11-14
$1.66M
derived: sum of 2 quarters · filed 2019-11-14
$2.37M
10-Q · filed 2019-11-14
$3.45M
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30$927.07K
10-Q · filed 2019-08-14
$1.63M
10-Q · filed 2019-08-14
$2.71M
derived: sum of 3 quarters · filed 2019-08-14
$3.60M
derived: sum of 4 quarters · filed 2019-08-14
2018-03-31$706.27K
10-Q · filed 2019-05-13
$1.79M
derived: sum of 2 quarters · filed 2019-05-13
$2.67M
derived: sum of 3 quarters · filed 2019-05-13
$3.55M
derived: sum of 4 quarters · filed 2019-05-13
2017-12-31$1.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29
$1.97M
derived: sum of 2 quarters · filed 2019-03-29
$2.84M
derived: sum of 3 quarters · filed 2019-03-29
$4.06M
10-K · filed 2019-03-29
2017-09-30$884.80K
10-Q · filed 2018-11-09
$1.76M
derived: sum of 2 quarters · filed 2018-11-09
$2.98M
10-Q · filed 2018-11-09
$43.19M
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30$873.84K
10-Q · filed 2018-08-10
$2.09M
10-Q · filed 2018-08-10
$2.09M
10-Q · filed 2017-08-14
$42.31M
derived: sum of 3 quarters · filed 2018-08-10
$43.20M
derived: sum of 4 quarters · filed 2018-08-10
2017-03-31$1.22M
10-Q · filed 2018-05-15
$41.43M
derived: sum of 2 quarters · filed 2018-05-15
$42.32M
derived: sum of 3 quarters · filed 2018-05-15
$44.53M
derived: sum of 4 quarters · filed 2018-05-15
2016-12-31$40.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30
$41.10M
derived: sum of 2 quarters · filed 2018-03-30
$43.31M
derived: sum of 3 quarters · filed 2018-03-30
$43.74M
10-K · filed 2018-03-30
2016-09-30$891.83K
10-Q · filed 2017-11-14
$3.10M
derived: sum of 2 quarters · filed 2017-11-14
$3.53M
10-Q · filed 2017-11-14
$4.55M
derived: sum of 4 quarters · filed 2017-11-14
2016-06-30$2.21M
10-Q · filed 2017-08-14
$2.63M
10-Q · filed 2017-08-14
$3.66M
derived: sum of 3 quarters · filed 2017-08-14
$4.48M
derived: sum of 4 quarters · filed 2017-08-14
2016-03-31$429.28K
10-Q · filed 2017-05-15
$1.46M
derived: sum of 2 quarters · filed 2017-05-15
$2.27M
derived: sum of 3 quarters · filed 2017-05-15
$2.83M
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31$1.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31
$1.84M
derived: sum of 2 quarters · filed 2017-03-31
$2.40M
derived: sum of 3 quarters · filed 2017-03-31
$3.43M
10-K · filed 2017-03-31
2015-09-30$816.32K
10-Q · filed 2016-11-14
$1.37M
derived: sum of 2 quarters · filed 2016-11-14
$2.41M
10-Q · filed 2016-11-14
$5.23M
derived: sum of 4 quarters · filed 2016-11-14
2015-06-30$555.74K
10-Q · filed 2016-08-15
$1.59M
10-Q · filed 2016-08-15
$4.41M
derived: sum of 3 quarters · filed 2016-08-15
$6.32M
derived: sum of 4 quarters · filed 2016-08-15
2015-03-31$1.04M
10-Q · filed 2016-05-16
$3.86M
derived: sum of 2 quarters · filed 2016-05-16
$5.76M
derived: sum of 3 quarters · filed 2016-05-16
$6.79M
derived: sum of 4 quarters · filed 2016-05-16
2014-12-31$2.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30
$4.73M
derived: sum of 2 quarters · filed 2016-03-30
$5.76M
derived: sum of 3 quarters · filed 2016-03-30
$6.32M
10-K · filed 2016-03-30
2014-09-30$1.91M
10-Q · filed 2015-11-16
$2.94M
derived: sum of 2 quarters · filed 2015-11-16
$3.50M
10-Q · filed 2015-11-16
$3.95M
derived: sum of 4 quarters · filed 2015-11-16
2014-06-30$1.03M
10-Q · filed 2015-08-19
$1.60M
10-Q · filed 2015-08-19
$2.04M
derived: sum of 3 quarters · filed 2015-08-19
$3.08M
derived: sum of 4 quarters · filed 2015-08-19
2014-03-31$564.89K
10-Q · filed 2015-05-20
$565.90K
10-Q · filed 2014-05-20
$1.01M
derived: sum of 2 quarters · filed 2015-07-20
$2.05M
derived: sum of 3 quarters · filed 2015-07-20
$3.00M
derived: sum of 4 quarters · filed 2015-07-20
2013-12-31$445.59K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-20
$1.48M
derived: sum of 2 quarters · filed 2015-07-20
$2.44M
derived: sum of 3 quarters · filed 2015-07-20
$3.06M
10-K · filed 2015-07-20
2013-09-30$1.04M
10-Q · filed 2014-11-14
$1.99M
derived: sum of 2 quarters · filed 2014-11-14
$2.61M
10-Q · filed 2014-11-14
2013-06-30$956.41K
10-Q · filed 2014-08-14
$1.58M
10-Q · filed 2014-08-14
2013-03-31$622.11K
10-Q · filed 2014-05-20
2012-12-31$1.94M
10-K · filed 2015-07-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
Pulmatrix, Inc. (PULM)United States$0.006B
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63